Xiaojiao Wang

23PUBLICATIONS
69CO-AUTHORS
Molecular targetsMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Sep 11, 2026
Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

|Sep 11, 2026
First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations.

|Aug 12, 2026
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

|Jul 11, 2026
Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication.

|Oct 08, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata

|May 29, 2025
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.

Saiying Ma, Xiaojia Wang, Peter Ping Lin

Pageof 4

Frequent Collaborators

5 joint publications

Wenming Cao

5 joint publications

Shusen Wang

4 joint publications

Tao Sun

3 joint publications

Ziyan Yang